Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo estradiol Clear all
Active, not recruiting Phase 3 Interventional Results available

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567
View directory record Official record
Conditions
Breast Neoplasm, Neoplasm Metastasis
Interventions
Abemaciclib, Fulvestrant, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
60
States / cities
Phoenix, Arizona • Springdale, Arkansas • Fullerton, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

NCT00754065
View directory record Official record
Conditions
Contraception
Interventions
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ortho Tri Cyclen Lo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
34
States / cities
Independence, Arizona • Phoenix, Arizona • Encinitas, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC

NCT00789802
View directory record Official record
Conditions
Contraception, Bleeding
Interventions
transdermal estradiol, naproxen, oral placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

NCT00293059
View directory record Official record
Conditions
Metrorrhagia
Interventions
Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
37
States / cities
Lake Havasu City, Arizona • Greenbrae, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.

NCT02668796
View directory record Official record
Conditions
Vulvar and Vaginal Atrophy
Interventions
Estradiol Vaginal Tablets 10 mcg (Glenmark), Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk), Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
522 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Mahwah, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021

NCT00544882
View directory record Official record
Conditions
Healthy
Interventions
DR-1021, Mircette®, Kariva®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Lawrenceville, New Jersey • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Topical Estriol for Vaginal Health

NCT00908570
View directory record Official record
Conditions
Vaginal Health
Interventions
estriol, Placebo
Drug
Lead sponsor
Gynuity Health Projects
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System

NCT00650442
View directory record Official record
Conditions
Healthy
Interventions
Estradiol Transdermal System Placebo - Alternate Adhesive, Estradiol Transdermal System Placebo - Current Adhesive
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 66 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

NCT05617820
View directory record Official record
Conditions
Dyspareunia
Interventions
Estradiol, Imvexxy, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
1,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
42
States / cities
Birmingham, Alabama • Chandler, Arizona • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

NCT02437318
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Alpelisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
34
States / cities
Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03271489
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
155
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 4 Interventional Results available

Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach

NCT04112368
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

NCT06308614
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Estetrol, Placebo
Drug · Other
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
24
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 28, 2026, 9:01 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives

NCT00089414
View directory record Official record
Conditions
Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression
Interventions
Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 28, 2026, 9:01 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women

NCT01633814
View directory record Official record
Conditions
Menopause, Aging, Blood Pressure
Interventions
Transdermal estradiol, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Timing Estrogen After MenoPaUSe

NCT01605071
View directory record Official record
Conditions
Insulin Resistance
Interventions
Estradiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 2Phase 3 Interventional

Alzheimer's Disease: Therapeutic Potential of Estrogen

NCT00066157
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Transdermal estradiol, Medroxyprogesterone, Placebo Patch, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 90 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

NCT00722761
View directory record Official record
Conditions
Acne Vulgaris
Interventions
drospirenone and ethinyl estradiol, Placebo tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Endogenous E2 on SSI and GH Rebound

NCT02026973
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Fulvestrant, Anastrozole, Placebo, Somatostatin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years to 80 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Reproductive Hormones on Mood and Behavior

NCT00001322
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Results available

Estrogen and Fear in PTSD

NCT04192266
View directory record Official record
Conditions
PTSD
Interventions
Estradiol, Placebo oral tablet, Prolonged Exposure (PE) therapy
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Anorexia Nervosa on Bone Mass in Adolescents

NCT00088153
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Physiologic Estrogen/progesterone, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Not applicable Interventional Results available

Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression

NCT01613131
View directory record Official record
Conditions
Menopausal and Other Perimenopausal Disorders
Interventions
Mirena, Estradiol, Placebo Gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 52 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 28, 2026, 9:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of Colchicine With an Oral Contraceptive

NCT01040845
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Norethindrone/Ethinyl Estradiol, Colchicine, Placebo (for Colchicine)
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2010 · Synced Sep 28, 2026, 9:01 PM EDT